Correia Ricardo, Fernandes Bárbara, Castro Rute, Nagaoka Hikaru, Takashima Eizo, Tsuboi Takafumi, Fukushima Akihisa, Viebig Nicola K, Depraetere Hilde, Alves Paula M, Roldão António
IBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
ITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.
Front Bioeng Biotechnol. 2022 Jun 30;10:908509. doi: 10.3389/fbioe.2022.908509. eCollection 2022.
The malaria asexual blood-stage antigen PfRipr and its most immunogenic fragment PfRipr5 have recently risen as promising vaccine candidates against this infectious disease. Continued development of high-yielding, scalable production platforms is essential to advance the malaria vaccine research. Insect cells have supplied the production of numerous vaccine antigens in a fast and cost-effective manner; improving this platform further could prove key to its wider use. In this study, insect (9 and High Five) and human (HEK293) cell hosts as well as process-optimizing strategies (new baculovirus construct designs and a culture temperature shift to hypothermic conditions) were employed to improve the production of the malaria asexual blood-stage vaccine candidate PfRipr5. Protein expression was maximized using High Five cells at CCI of 2 × 10 cell/mL and MOI of 0.1 pfu/cell (production yield = 0.49 mg/ml), with high-purity PfRipr5 binding to a conformational anti-PfRipr monoclonal antibody known to hold GIA activity and parasite PfRipr staining capacity. Further improvements in the PfRipr5 expression were achieved by designing novel expression vector sequences and performing a culture temperature shift to hypothermic culture conditions. Addition of one alanine (A) amino acid residue adjacent to the signal peptide cleavage site and a glycine-serine linker (GGSGG) between the PfRipr5 sequence and the purification tag (His) induced a 2.2-fold increase in the expression of secreted PfRipr5 over using the expression vector with none of these additions. Performing a culture temperature shift from the standard 27-22°C at the time of infection improved the PfRipr5 expression by up to 1.7 fold. Notably, a synergistic effect was attained when combining both strategies, enabling to increase production yield post-purification by 5.2 fold, with similar protein quality (i.e., purity and binding to anti-PfRipr monoclonal antibody). This work highlights the potential of insect cells to produce the PfRipr5 malaria vaccine candidate and the importance of optimizing the expression vector and culture conditions to boost the expression of secreted proteins.
疟疾无性血液期抗原PfRipr及其免疫原性最强的片段PfRipr5,最近已成为抗这种传染病的有前景的疫苗候选物。持续开发高产、可扩展的生产平台对于推进疟疾疫苗研究至关重要。昆虫细胞已快速且经济高效地提供了多种疫苗抗原的生产;进一步改进该平台可能是其更广泛应用的关键。在本研究中,采用昆虫(9和High Five)和人(HEK293)细胞宿主以及工艺优化策略(新的杆状病毒构建体设计和将培养温度转变为低温条件)来提高疟疾无性血液期疫苗候选物PfRipr5的产量。在细胞浓度为2×10⁶细胞/mL和感染复数为0.1 pfu/细胞的条件下,使用High Five细胞使蛋白质表达最大化(产量 = 0.49 mg/ml),高纯度的PfRipr5与已知具有GIA活性和寄生虫PfRipr染色能力的构象抗PfRipr单克隆抗体结合。通过设计新的表达载体序列并将培养温度转变为低温培养条件,PfRipr5的表达得到了进一步改善。在信号肽切割位点相邻处添加一个丙氨酸(A)氨基酸残基,并在PfRipr5序列与纯化标签(His)之间添加一个甘氨酸 - 丝氨酸接头(GGSGG),与未添加这些的表达载体相比,分泌型PfRipr5的表达增加了2.2倍。在感染时将培养温度从标准的27°C转变为22°C,可使PfRipr5的表达提高多达1.7倍。值得注意的是,将两种策略结合可产生协同效应,使纯化后的产量提高5.2倍,且蛋白质质量相似(即纯度和与抗PfRipr单克隆抗体的结合)。这项工作突出了昆虫细胞生产PfRipr5疟疾疫苗候选物的潜力,以及优化表达载体和培养条件以提高分泌蛋白表达的重要性。